FDA rejects J&J’s subcutaneous Rybrevant over manufacturing issues
The FDA has issued a complete response letter to Johnson & Johnson for the subcutaneous version of its lung cancer drug Rybrevant after issues were …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
